Data shows that 51% of participants achieved sustained unresponsiveness (clinical remission) to peanut after 18 months of treatment
Prota Therapeutics, an Australian biotechnology company focused on the development of novel oral immunotherapy treatments, has achieved a significant milestone in the treatment of peanut allergy in children.
Published in The Lancet Child & Adolescent Health, the Phase 2b clinical trial results validate Prota’s lead product candidate PRT120.
PRT120 is an investigational oral immunotherapy with a novel high dose, rapid escalation dosing regimen for the treatment of peanut allergy. The placebo-controlled trial confirms the effectiveness of PRT120 comprising Prota’s rapid escalation dosing regimen in inducing clinical remission of peanut allergy in children and improving quality of life for patients.
Remission of allergy refers to the absence of clinical reactivity that persists after treatment has been stopped for a period of time. This allows patients to stop treatment and no longer adhere to strict allergen avoidance.
Previous studies of peanut oral immunotherapy have shown limited success at stimulating remission, with only a small subset of patients achieving this endpoint after years of treatment. In this new trial, 51% of children achieved remission after 18 months, compared to 5% in the placebo arm, recording the highest rate of remission yet reported for a standalone peanut oral immunotherapy treatment in school-aged children.
The paediatric peanut allergy market is estimated to be worth $3 billion by 2027, with around 1.1 million patients between the ages of 1-17 diagnosed in the US alone last year.